← Back to Search

Cohort 3 for Heart Failure (RESPECT Trial)

N/A
Waitlist Available
Research Sponsored by WakeMed Health and Hospitals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 month
Awards & highlights

RESPECT Trial Summary

This trial is testing a device that monitors various vital signs to see if it can predict when heart failure patients are about to have a health decline and be readmitted to the hospital.

Eligible Conditions
  • Heart Failure

RESPECT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Aidar Questionnaire to Evaluate Patient Perception of Heart Failure
Evaluate trends of blood oxygen saturation (SpO2) in percentage
Evaluate trends of blood pressure measured in mm/Hg
+10 more

RESPECT Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort 3Experimental Treatment1 Intervention
Stable outpatients with implantable CardioMEMS devices
Group II: Cohort 2Experimental Treatment1 Intervention
Stable outpatients with Boston Scientific pacemakers or defibrillators with Heart Logic capability
Group III: Cohort 1Experimental Treatment1 Intervention
Stable outpatients without implantable devices

Find a Location

Who is running the clinical trial?

WakeMed Health and HospitalsLead Sponsor
5 Previous Clinical Trials
3,639 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
CirculationJournal
Heart Disease and Stroke Statistics—2019 Update: A Report from the American Heart Association
Benjamin, Emelia J., Paul Muntner, Alvaro Alonso, Marcio S. Bittencourt, Clifton W. Callaway, April P. Carson, Alanna M. Chamberlain, et al.. 2019. “Heart Disease and Stroke Statistics—2019 Update: A Report from the American Heart Association”. Circulation. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/cir.0000000000000659.
Circulation: Heart FailureJournal
Forecasting the Impact of Heart Failure in the United States
Heidenreich, Paul A., Nancy M. Albert, Larry A. Allen, David A. Bluemke, Javed Butler, Gregg C. Fonarow, John S. Ikonomidis, et al.. 2013. “Forecasting the Impact of Heart Failure in the United States”. Circulation: Heart Failure. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/hhf.0b013e318291329a.
CirculationJournal
Heart Disease and Stroke Statistics—2016 Update
Mozaffarian, Dariush, Emelia J. Benjamin, Alan S. Go, Donna K. Arnett, Michael J. Blaha, Mary Cushman, Sandeep R. Das, et al.. 2016. “Heart Disease and Stroke Statistics—2016 Update”. Circulation. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/cir.0000000000000350.
Journal of General Internal MedicineJournal
Development and Testing of a New Measure of Health Status for Clinical Trials in Heart Failure
Guyatt, Gordon H., Sharon Nogradi, Susan Halcrow, Joel Singer, Michael J. J. Sullivan, and Ernest L. Fallen. 1989. “Development and Testing of a New Measure of Health Status for Clinical Trials in Heart Failure”. Journal of General Internal Medicine. Springer Science and Business Media LLC. doi:10.1007/bf02602348.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top